BASF and chemical giants building new MDI plant
pharmafile | July 1, 2014 | News story | Manufacturing and Production | BASF, China, Huntsman, SINOPEC, Shanghai, Shanghai Chlor-Alkali, Shanghai Hua Yi, mdi
BASF, Huntsman, Shanghai Hua Yi, Shanghai Chlor-Alkali and SINOPEC are teaming up to construct a new MDI plant in China.
The facility that is planned to kick-start in 2017, aims to have a production capacity of 240,000 metric tons of crude MDI (diphenylmethane diisocyanate).
Based at Shanghai Lianheng Isocyanate in Caojing, the new installation means the MDI capacity and output at the site will total 480,000 metric tons per year combined.
In addition, the partners plan to build a HCl (hydrogen chloride) recycling plant for the production of chlorine, a precursor for MDI.
MDI is an important precursor in the manufacture of polyurethanes – versatile polymers that are used primarily in industries like construction, automotive, appliance, and footwear.
Martin Brudermüller, vice chairman of the board of executive directors at BASF says: “Asia-Pacific remains an important growth and investment region for BASF, with the fast-growing Chinese market being a major focus.”
The new MDI plant is planned at the Shanghai Chemical Industry Park (SCIP) in Caojing, adjacent to an existing integrated isocyanates complex. This will enable the utilisation and full access to raw materials and energy.
Shanghai Lianheng Isocyanate (SLIC) has a production capacity of 240,000 metric tons of crude MDI per year and includes manufacturing facilities for the precursors aniline and nitrobenzene built by BASF, Huntsman, Shanghai Hua Yi, Shanghai Chlor-Alkali Chemical and SINOPEC. Commercial production started in 2006.
The facility is expected to start in three years time and the project is subject to further approval of the Chinese Ministry of Commerce.
Brett Wells
Related Content
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission …
